Robin Wigglesworth’s Friday roundup today spotlights the pharmaceuticals sector, urging subscribers to sign up for the FT Digest. Among the links, Eli Lilly’s decision to grant an experimental obesity drug to a 79‑year‑old patient draws attention for its global humanitarian optics and potential regulatory scrutiny. The note hints that the patient may soon turn 80, underscoring the drug’s real‑world rollout.

The list points to a Baffler article on Antifa’s origins, a Bloomberg column where Nouriel Roubini finds a niche for blockchain, and an SSRN study highlighting north‑south discrimination in England. A Hollywood Reporter piece warns of a brewing clash between studios and Big Tech, while Persuasion urges an international treaty to curb superintelligence. Norway‑born striker Erling Haaland tells the BBC he simply excels at scoring.

For investors, the curated pieces signal heightened scrutiny of drug access decisions and growing regulatory risk for companies like Eli Lilly. Simultaneously, the tech‑media friction and AI governance debate suggest broader policy headwinds that could reshape capital allocation across health, entertainment and emerging tech sectors. Readers are left with a checklist of issues demanding immediate board‑level attention.